Director, Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse
Kurt Rasmussen, M.D., is an internationally recognized neuroscientist, who specializes in basic addiction research and drug development. Dr. Rasmussen has extensive knowledge of neuropsychiatric and neurological therapeutics and is known for his expertise in pharmaceutical discovery research from hypothesis generation to clinical candidate evaluation. As Director of the Division of Therapeutics and Medical Consequences, Dr. Rasmussen directs NIDA’s Medications Development Program, evaluating the safety and efficacy of pharmacotherapies, behavioral therapies, and devices to treat substance use disorders through peer reviewed grants, contracts, and interagency agreements. Previous experience includes 28 years at Eli Lilly. He joined the National Institute on Drug Abuse in April 2018.